Xencor, Inc. $XNCR Shares Purchased by DCF Advisers LLC

DCF Advisers LLC boosted its stake in Xencor, Inc. (NASDAQ:XNCR) by 35.5% during the third quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 189,736 shares of the biopharmaceutical company’s stock after buying an additional 49,736 shares during the quarter. DCF Advisers LLC owned approximately 0.27% of Xencor worth $2,226,000 as of its most recent filing with the SEC.

Other hedge funds also recently bought and sold shares of the company. Hantz Financial Services Inc. raised its holdings in shares of Xencor by 209.1% in the third quarter. Hantz Financial Services Inc. now owns 3,187 shares of the biopharmaceutical company’s stock worth $37,000 after acquiring an additional 2,156 shares during the last quarter. GAMMA Investing LLC boosted its stake in shares of Xencor by 77.1% during the third quarter. GAMMA Investing LLC now owns 3,328 shares of the biopharmaceutical company’s stock valued at $39,000 after acquiring an additional 1,449 shares during the last quarter. Farther Finance Advisors LLC acquired a new stake in shares of Xencor during the third quarter valued at $44,000. Federated Hermes Inc. increased its position in Xencor by 114.3% during the 3rd quarter. Federated Hermes Inc. now owns 3,947 shares of the biopharmaceutical company’s stock worth $46,000 after purchasing an additional 2,105 shares in the last quarter. Finally, Nisa Investment Advisors LLC raised its stake in Xencor by 85.5% in the 3rd quarter. Nisa Investment Advisors LLC now owns 5,260 shares of the biopharmaceutical company’s stock valued at $62,000 after purchasing an additional 2,424 shares during the last quarter.

Analyst Upgrades and Downgrades

A number of research firms have issued reports on XNCR. Wall Street Zen lowered shares of Xencor from a “hold” rating to a “sell” rating in a report on Saturday, February 28th. Barclays lifted their price target on shares of Xencor from $26.00 to $27.00 and gave the stock an “overweight” rating in a report on Thursday, February 26th. Weiss Ratings reissued a “sell (d-)” rating on shares of Xencor in a research report on Monday, December 29th. Finally, Truist Financial began coverage on shares of Xencor in a research note on Monday, November 24th. They set a “buy” rating and a $29.00 price objective on the stock. Eight equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $25.00.

Insiders Place Their Bets

In other news, VP John R. Desjarlais sold 2,663 shares of the company’s stock in a transaction on Tuesday, March 3rd. The stock was sold at an average price of $11.90, for a total transaction of $31,689.70. Following the completion of the sale, the vice president directly owned 270,451 shares in the company, valued at $3,218,366.90. This represents a 0.98% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, CEO Bassil I. Dahiyat sold 6,758 shares of Xencor stock in a transaction on Tuesday, March 3rd. The shares were sold at an average price of $11.90, for a total value of $80,420.20. Following the completion of the transaction, the chief executive officer owned 567,792 shares in the company, valued at $6,756,724.80. The trade was a 1.18% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last 90 days, insiders have sold 198,657 shares of company stock valued at $3,080,057. Insiders own 4.76% of the company’s stock.

Xencor Stock Performance

Shares of XNCR stock opened at $11.32 on Friday. The company has a debt-to-equity ratio of 0.12, a quick ratio of 6.25 and a current ratio of 6.25. The firm has a market capitalization of $830.21 million, a price-to-earnings ratio of -9.13 and a beta of 0.95. Xencor, Inc. has a one year low of $6.92 and a one year high of $18.69. The company has a 50 day moving average price of $12.79 and a 200 day moving average price of $12.93.

Xencor (NASDAQ:XNCR) last announced its quarterly earnings results on Wednesday, February 25th. The biopharmaceutical company reported ($0.09) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.64) by $0.55. The company had revenue of $28.24 million for the quarter, compared to analyst estimates of $29.97 million. Xencor had a negative net margin of 73.20% and a negative return on equity of 14.58%. Xencor’s revenue for the quarter was down 46.6% on a year-over-year basis. During the same quarter last year, the business earned ($0.62) EPS. Sell-side analysts anticipate that Xencor, Inc. will post -3.68 EPS for the current year.

Xencor Company Profile

Xencor, Inc is a clinical-stage biopharmaceutical company focused on the design and development of engineered protein therapeutics for the treatment of autoimmune diseases, cancer and neurological disorders. The company applies its proprietary XmAb® platform to manipulate antibody structure and function, creating molecules with enhanced immune engagement and extended half-life. Xencor’s research programs span a range of therapeutic modalities, including monoclonal antibodies, bispecific antibodies and cytokine-based fusion proteins.

The XmAb® platform enables precise modification of the Fc region to augment key properties such as receptor binding, effector function and pharmacokinetics.